<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Clinical Trial NDA | Biotech Trial Collaborations | Terms.Law</title>
  <meta name="description" content="NDA templates for clinical trial collaborations, investigator-initiated studies, and multi-site trials. Includes IRB alignment, adverse event provisions, publication rights, and regulatory submission clauses.">
  <link rel="canonical" href="https://terms.law/NDA/industry-packs/biotech/clinical-trial-nda.html">

  <script type="application/ld+json">
  {"@context":"https://schema.org","@type":"FAQPage","mainEntity":[
  {"@type":"Question","name":"What special provisions do biotech clinical trial NDAs require?","acceptedAnswer":{"@type":"Answer","text":"Biotech clinical trial NDAs require provisions for: IRB protocol alignment, adverse event reporting exceptions, patient safety data sharing, publication timing for patent protection, regulatory submission rights, data ownership between sponsors and investigators, and multi-site coordination requirements."}},
  {"@type":"Question","name":"How do clinical trial NDAs handle adverse event reporting?","acceptedAnswer":{"@type":"Answer","text":"Adverse event reporting must supersede confidentiality. NDAs include carve-outs permitting immediate safety reporting to sponsors (24h for serious events), FDA reporting (7-15 days depending on severity), IRB notification, and DSMB communications. These disclosures do not constitute breaches."}},
  {"@type":"Question","name":"Who owns clinical trial data under a biotech NDA?","acceptedAnswer":{"@type":"Answer","text":"Ownership varies by arrangement: Sponsors typically own raw trial data, CRFs, and regulatory submission rights. Investigators may retain rights to publish and use aggregated findings. Academic institutions often negotiate perpetual licenses. The NDA should clearly define ownership, usage rights, and what happens upon termination."}},
  {"@type":"Question","name":"Can investigators publish clinical trial results?","acceptedAnswer":{"@type":"Answer","text":"Most agreements grant publication rights subject to: a review period (typically 30-90 days), sponsor right to request removal of confidential information, patent filing delays, multi-site publication coordination, and acknowledgment requirements. Indefinite publication bans are disfavored and may violate research ethics."}}
  ]}
  </script>

  <!-- Google Analytics -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-901N2Y3CDZ"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    gtag('config', 'G-901N2Y3CDZ');
  </script>

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <style>
    :root {
      --primary: #2563eb;
      --primary-dark: #1d4ed8;
      --accent: #8b5cf6;
      --success: #10b981;
      --warning: #f59e0b;
      --danger: #ef4444;
      --biotech: #7c3aed;
      --biotech-dark: #6d28d9;
      --biotech-light: #f5f3ff;
      --clinical: #0891b2;
      --clinical-dark: #0e7490;
      --clinical-light: #ecfeff;
      --dark: #0f172a;
      --dark-lighter: #1e293b;
      --gray-50: #f8fafc;
      --gray-100: #f1f5f9;
      --gray-200: #e2e8f0;
      --gray-300: #cbd5e1;
      --gray-400: #94a3b8;
      --gray-500: #64748b;
      --gray-600: #475569;
      --gray-700: #334155;
      --gray-800: #1e293b;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }
    body {
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
      background: var(--gray-50);
      color: var(--gray-700);
      line-height: 1.6;
    }

    /* Header Styles */
    .site-header {
        background: linear-gradient(135deg, #0f172a 0%, #1e293b 100%);
        position: sticky;
        top: 0;
        z-index: 1000;
        box-shadow: 0 4px 20px rgba(0,0,0,0.3);
    }
    .header-content {
        max-width: 1400px;
        margin: 0 auto;
        display: flex;
        align-items: center;
        padding: 0 24px;
        height: 60px;
    }
    .site-logo {
        font-size: 1.15rem;
        font-weight: 800;
        text-decoration: none;
        background: linear-gradient(135deg, #60a5fa 0%, #a78bfa 100%);
        -webkit-background-clip: text;
        -webkit-text-fill-color: transparent;
        margin-right: 32px;
    }
    .site-nav {
        display: flex;
        align-items: center;
        gap: 0;
        flex: 1;
    }
    .nav-link {
        padding: 18px 16px;
        color: #94a3b8;
        text-decoration: none;
        font-size: 14px;
        font-weight: 500;
        transition: all 0.2s;
    }
    .nav-link:hover { color: #fff; }
    .nav-cta {
        margin-left: auto;
        background: linear-gradient(135deg, #2563eb 0%, #7c3aed 100%);
        color: #fff !important;
        padding: 10px 20px !important;
        border-radius: 8px;
        font-weight: 600 !important;
    }

    /* Breadcrumb */
    .breadcrumb {
      background: var(--gray-100);
      padding: 12px 24px;
      font-size: 0.85rem;
    }
    .breadcrumb-inner {
      max-width: 1400px;
      margin: 0 auto;
    }
    .breadcrumb a {
      color: var(--gray-500);
      text-decoration: none;
    }
    .breadcrumb a:hover {
      color: var(--biotech);
    }
    .breadcrumb span {
      color: var(--gray-400);
      margin: 0 8px;
    }
    .breadcrumb .current {
      color: var(--gray-700);
      font-weight: 600;
    }

    /* Hub Sub-Navigation */
    .hub-subnav {
      background: linear-gradient(135deg, #6d28d9 0%, #7c3aed 100%);
    }
    .hub-subnav-content {
      max-width: 1400px;
      margin: 0 auto;
      padding: 0 24px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      height: 48px;
    }
    .hub-subnav-title {
      color: #fff;
      font-size: 0.9rem;
      font-weight: 700;
      text-decoration: none;
    }
    .hub-subnav-tabs { display: flex; gap: 8px; }
    .hub-tab {
      padding: 8px 16px;
      color: rgba(255,255,255,0.8);
      text-decoration: none;
      font-size: 0.85rem;
      font-weight: 500;
      border-radius: 6px;
      transition: all 0.2s;
    }
    .hub-tab:hover { background: rgba(255,255,255,0.15); color: #fff; }
    .hub-tab.active { background: rgba(255,255,255,0.2); color: #fff; }

    /* Hero */
    .hero {
      background: linear-gradient(135deg, #0e7490 0%, #0891b2 50%, #06b6d4 100%);
      padding: 3rem 2rem;
    }
    .hero-inner {
      max-width: 900px;
      margin: 0 auto;
      text-align: center;
    }
    .hero-badge {
      display: inline-flex;
      align-items: center;
      gap: 8px;
      background: rgba(255,255,255,0.15);
      border: 1px solid rgba(255,255,255,0.3);
      padding: 6px 16px;
      border-radius: 100px;
      font-size: 0.8rem;
      color: #fff;
      margin-bottom: 1.5rem;
    }
    .hero h1 {
      font-size: 2.5rem;
      font-weight: 800;
      color: white;
      margin-bottom: 1rem;
    }
    .hero-sub {
      font-size: 1.1rem;
      color: rgba(255,255,255,0.9);
      max-width: 650px;
      margin: 0 auto;
    }

    /* Main Content */
    .main-content {
      max-width: 1200px;
      margin: 0 auto;
      padding: 3rem 2rem;
    }

    /* Trial Types */
    .trial-types {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 1.5rem;
      margin-bottom: 3rem;
    }
    @media (max-width: 900px) { .trial-types { grid-template-columns: 1fr; } }
    .trial-type-card {
      background: white;
      border: 2px solid var(--gray-200);
      border-radius: 16px;
      padding: 1.5rem;
      transition: all 0.3s;
    }
    .trial-type-card:hover {
      border-color: var(--clinical);
      transform: translateY(-4px);
    }
    .trial-type-icon {
      font-size: 2rem;
      margin-bottom: 1rem;
    }
    .trial-type-card h3 {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--dark);
      margin-bottom: 0.5rem;
    }
    .trial-type-card p {
      font-size: 0.9rem;
      color: var(--gray-600);
    }

    /* Section Styles */
    .section { margin-bottom: 3rem; }
    .section h2 {
      font-size: 1.75rem;
      font-weight: 800;
      color: var(--dark);
      margin-bottom: 1.5rem;
      display: flex;
      align-items: center;
      gap: 12px;
    }

    /* Phase Section */
    .phase-section {
      background: var(--clinical-light);
      border: 2px solid #a5f3fc;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .phase-section h2 { color: var(--clinical-dark); }
    .phase-grid {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 1rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 900px) { .phase-grid { grid-template-columns: repeat(2, 1fr); } }
    .phase-card {
      background: white;
      border-radius: 10px;
      padding: 1.25rem;
      text-align: center;
    }
    .phase-number {
      font-size: 1.5rem;
      font-weight: 800;
      color: var(--clinical);
      margin-bottom: 0.5rem;
    }
    .phase-card h4 {
      font-size: 0.9rem;
      font-weight: 700;
      color: var(--dark);
      margin-bottom: 0.25rem;
    }
    .phase-card p {
      font-size: 0.8rem;
      color: var(--gray-600);
    }

    /* Adverse Event Section */
    .adverse-section {
      background: #fef2f2;
      border: 2px solid #fecaca;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .adverse-section h2 { color: #991b1b; }
    .adverse-timeline {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 1rem;
      margin: 1.5rem 0;
    }
    @media (max-width: 768px) { .adverse-timeline { grid-template-columns: repeat(2, 1fr); } }
    .adverse-item {
      background: white;
      border-radius: 10px;
      padding: 1rem;
      text-align: center;
    }
    .adverse-hours {
      font-size: 1.5rem;
      font-weight: 800;
      color: #dc2626;
    }
    .adverse-label {
      font-size: 0.75rem;
      color: var(--gray-600);
      margin-top: 0.25rem;
    }

    /* Data Ownership */
    .ownership-section {
      background: white;
      border: 2px solid var(--gray-200);
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .ownership-grid {
      display: grid;
      grid-template-columns: repeat(2, 1fr);
      gap: 1.5rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 768px) { .ownership-grid { grid-template-columns: 1fr; } }
    .ownership-party {
      border: 2px solid var(--gray-200);
      border-radius: 12px;
      padding: 1.5rem;
    }
    .ownership-party.sponsor { border-color: var(--clinical); background: var(--clinical-light); }
    .ownership-party h4 {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--dark);
      margin-bottom: 0.75rem;
      display: flex;
      align-items: center;
      gap: 8px;
    }
    .ownership-list {
      list-style: none;
    }
    .ownership-list li {
      font-size: 0.9rem;
      color: var(--gray-600);
      padding: 0.5rem 0;
      border-bottom: 1px solid var(--gray-100);
      display: flex;
      align-items: center;
      gap: 8px;
    }
    .ownership-list li:last-child { border-bottom: none; }
    .ownership-list li::before {
      content: "\2022";
      color: var(--clinical);
      font-weight: bold;
    }

    /* Publication Rights */
    .publication-section {
      background: #fffbeb;
      border: 2px solid #fcd34d;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .publication-section h2 { color: #92400e; }
    .publication-timeline {
      display: flex;
      align-items: center;
      justify-content: space-between;
      margin: 2rem 0;
      position: relative;
    }
    .publication-timeline::before {
      content: '';
      position: absolute;
      top: 20px;
      left: 60px;
      right: 60px;
      height: 4px;
      background: #fcd34d;
    }
    .timeline-point {
      text-align: center;
      position: relative;
      z-index: 1;
    }
    .timeline-dot {
      width: 40px;
      height: 40px;
      background: #f59e0b;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      color: white;
      font-weight: 700;
      font-size: 0.9rem;
      margin: 0 auto 0.5rem;
    }
    .timeline-label {
      font-size: 0.75rem;
      color: var(--gray-600);
      max-width: 100px;
    }
    @media (max-width: 768px) {
      .publication-timeline { flex-direction: column; gap: 1.5rem; }
      .publication-timeline::before { display: none; }
    }

    /* IRB Section */
    .irb-section {
      background: var(--biotech-light);
      border: 2px solid #c4b5fd;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .irb-section h2 { color: var(--biotech-dark); }
    .irb-grid {
      display: grid;
      grid-template-columns: repeat(2, 1fr);
      gap: 1rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 768px) { .irb-grid { grid-template-columns: 1fr; } }
    .irb-item {
      background: white;
      border-radius: 10px;
      padding: 1rem;
      display: flex;
      align-items: flex-start;
      gap: 12px;
    }
    .irb-item-icon {
      font-size: 1.25rem;
      flex-shrink: 0;
    }
    .irb-item h4 {
      font-size: 0.95rem;
      font-weight: 600;
      color: var(--dark);
      margin-bottom: 0.25rem;
    }
    .irb-item p {
      font-size: 0.85rem;
      color: var(--gray-600);
    }

    /* Sample Clause */
    .sample-clause {
      background: var(--gray-50);
      border-left: 4px solid var(--clinical);
      padding: 1rem;
      font-size: 0.85rem;
      font-style: italic;
      color: var(--gray-600);
      border-radius: 0 8px 8px 0;
      margin-top: 1rem;
    }

    /* Generator CTA */
    .generator-cta {
      background: linear-gradient(135deg, var(--clinical) 0%, var(--clinical-dark) 100%);
      border-radius: 16px;
      padding: 2.5rem;
      text-align: center;
      margin-bottom: 3rem;
    }
    .generator-cta h2 {
      font-size: 1.75rem;
      font-weight: 800;
      color: white;
      margin-bottom: 0.5rem;
    }
    .generator-cta p {
      color: rgba(255,255,255,0.9);
      margin-bottom: 1.5rem;
    }
    .generator-cta .btn {
      background: white;
      color: var(--clinical-dark);
      padding: 1rem 2rem;
      border-radius: 10px;
      font-weight: 700;
      font-size: 1rem;
      text-decoration: none;
      display: inline-block;
      transition: all 0.2s;
    }
    .generator-cta .btn:hover {
      transform: translateY(-2px);
      box-shadow: 0 10px 20px rgba(0,0,0,0.2);
    }

    /* Attorney Disclaimer */
    .attorney-disclaimer {
      background: #f0f9ff;
      border: 2px solid #0ea5e9;
      border-radius: 12px;
      padding: 1.5rem;
      text-align: center;
      margin-bottom: 3rem;
    }
    .attorney-disclaimer h4 {
      color: #0369a1;
      font-size: 1rem;
      font-weight: 700;
      margin-bottom: 0.5rem;
    }
    .attorney-disclaimer p {
      color: #0c4a6e;
      font-size: 0.9rem;
    }
    .attorney-disclaimer a {
      color: #0369a1;
      font-weight: 600;
    }

    /* Footer */
    .footer {
      background: var(--dark);
      padding: 3rem 2rem;
      color: var(--gray-300);
    }
    .footer-inner {
      max-width: 1200px;
      margin: 0 auto;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }
    .footer-links { display: flex; gap: 2rem; }
    .footer-links a {
      color: var(--gray-300);
      text-decoration: none;
      font-size: 0.9rem;
    }
    .footer-links a:hover { color: white; }

    @media (max-width: 768px) {
      .hero h1 { font-size: 2rem; }
      .footer-inner { flex-direction: column; gap: 1rem; text-align: center; }
      .hub-subnav-tabs { display: none; }
    }
  </style>
</head>
<body>

<!-- Header -->
<header class="site-header">
    <div class="header-content">
        <a href="/" class="site-logo">Terms.Law</a>
        <nav class="site-nav">
            <a href="/NDA/" class="nav-link">NDA Studio</a>
            <a href="/NDA/industry-packs/" class="nav-link">Industry Packs</a>
            <a href="/NDA/clause-library/" class="nav-link">Clause Library</a>
            <a href="mailto:owner@terms.law" class="nav-link nav-cta">Contact</a>
        </nav>
    </div>
</header>

<!-- Breadcrumb -->
<nav class="breadcrumb">
  <div class="breadcrumb-inner">
    <a href="/">Terms.Law</a>
    <span>&#8250;</span>
    <a href="/NDA/">NDA Studio</a>
    <span>&#8250;</span>
    <a href="/NDA/industry-packs/">Industry Packs</a>
    <span>&#8250;</span>
    <a href="./">Biotech</a>
    <span>&#8250;</span>
    <span class="current">Clinical Trial NDA</span>
  </div>
</nav>

<!-- Hub Sub-Navigation -->
<nav class="hub-subnav">
  <div class="hub-subnav-content">
    <a href="./" class="hub-subnav-title">&#129516; Biotech NDA Pack</a>
    <div class="hub-subnav-tabs">
      <a href="./" class="hub-tab">Overview</a>
      <a href="clinical-trial-nda.html" class="hub-tab active">Clinical Trials</a>
      <a href="compound-licensing-nda.html" class="hub-tab">Licensing</a>
      <a href="research-collaboration-nda.html" class="hub-tab">Research</a>
      <a href="cro-cmo-nda.html" class="hub-tab">CRO/CMO</a>
      <a href="fda-submission-nda.html" class="hub-tab">FDA Filings</a>
    </div>
  </div>
</nav>

<!-- Hero -->
<section class="hero">
  <div class="hero-inner">
    <div class="hero-badge">
      <span>&#129514;</span> Clinical Development
    </div>
    <h1>Clinical Trial NDA</h1>
    <p class="hero-sub">
      Specialized NDA provisions for clinical trial collaborations, investigator-initiated studies, and multi-site trial coordination. Protects protocol data while enabling required safety reporting.
    </p>
  </div>
</section>

<!-- Main Content -->
<div class="main-content">

  <!-- Trial Types -->
  <div class="trial-types">
    <div class="trial-type-card">
      <div class="trial-type-icon">&#128202;</div>
      <h3>Sponsor-Investigator</h3>
      <p>Pharma/biotech sponsors engaging clinical investigators for trial conduct.</p>
    </div>
    <div class="trial-type-card">
      <div class="trial-type-icon">&#127891;</div>
      <h3>Investigator-Initiated</h3>
      <p>Academic-led studies with industry compound or data access.</p>
    </div>
    <div class="trial-type-card">
      <div class="trial-type-icon">&#127981;</div>
      <h3>Multi-Site Coordination</h3>
      <p>Central coordination of multi-center trials with data sharing.</p>
    </div>
  </div>

  <!-- Trial Phase Considerations -->
  <section class="phase-section">
    <h2>&#128200; Phase-Specific Considerations</h2>
    <p>Confidentiality needs vary by development phase. Earlier phases have greater competitive sensitivity.</p>

    <div class="phase-grid">
      <div class="phase-card">
        <div class="phase-number">I</div>
        <h4>First-in-Human</h4>
        <p>Maximum protection; compound structure often undisclosed</p>
      </div>
      <div class="phase-card">
        <div class="phase-number">II</div>
        <h4>Proof of Concept</h4>
        <p>Efficacy signals highly competitive; dosing data protected</p>
      </div>
      <div class="phase-card">
        <div class="phase-number">III</div>
        <h4>Pivotal Trials</h4>
        <p>Registration data critical; multi-site coordination complex</p>
      </div>
      <div class="phase-card">
        <div class="phase-number">IV</div>
        <h4>Post-Market</h4>
        <p>Safety data sharing; real-world evidence protection</p>
      </div>
    </div>

    <div class="sample-clause">
      Investigator acknowledges that the Study Drug is in Phase [I/II/III] development and that all information regarding the Study Drug's mechanism of action, pharmacokinetic profile, efficacy signals, and safety findings constitutes Confidential Information of the highest competitive sensitivity, warranting enhanced protection measures as specified herein.
    </div>
  </section>

  <!-- Adverse Event Reporting -->
  <section class="adverse-section">
    <h2>&#128680; Adverse Event Reporting Exception</h2>
    <p>Patient safety supersedes confidentiality. NDAs must include clear carve-outs for required safety reporting.</p>

    <div class="adverse-timeline">
      <div class="adverse-item">
        <div class="adverse-hours">24h</div>
        <div class="adverse-label">Fatal/life-threatening events to sponsor</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">7d</div>
        <div class="adverse-label">IND Safety Reports to FDA (fatal/life-threatening)</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">15d</div>
        <div class="adverse-label">Serious unexpected AEs to FDA</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">Ongoing</div>
        <div class="adverse-label">IRB and DSMB notifications</div>
      </div>
    </div>

    <div class="sample-clause">
      Notwithstanding any confidentiality obligations herein, Investigator shall immediately report to Sponsor any serious adverse event as defined in 21 CFR 312.32, and shall cooperate with Sponsor's safety reporting obligations to FDA, IRBs, and data safety monitoring boards. Such safety-related disclosures shall not constitute a breach of this Agreement. Sponsor may disclose safety information to regulatory authorities, ethics committees, and other investigators as required to protect patient safety.
    </div>
  </section>

  <!-- Data Ownership -->
  <section class="ownership-section">
    <h2>&#128202; Clinical Data Ownership</h2>
    <p>Clear delineation of data ownership prevents disputes and enables appropriate use by both parties.</p>

    <div class="ownership-grid">
      <div class="ownership-party sponsor">
        <h4>&#127970; Sponsor Typically Owns</h4>
        <ul class="ownership-list">
          <li>Raw clinical trial data and CRFs</li>
          <li>Statistical analyses and CSRs</li>
          <li>Regulatory submission rights</li>
          <li>Study drug information</li>
          <li>Protocol and amendments</li>
        </ul>
      </div>
      <div class="ownership-party">
        <h4>&#127891; Investigator May Retain</h4>
        <ul class="ownership-list">
          <li>Right to publish (with review)</li>
          <li>Use of aggregated findings</li>
          <li>Source documents (with access)</li>
          <li>General scientific knowledge</li>
          <li>Patient treatment decisions</li>
        </ul>
      </div>
    </div>

    <div class="sample-clause">
      All Clinical Trial Data, including case report forms, laboratory results, imaging studies, and statistical analyses, shall be owned exclusively by Sponsor. Investigator shall retain physical custody of source documents at the Study Site, subject to Sponsor's right of access for monitoring, audit, and regulatory purposes. Upon Sponsor's request or Study termination, Investigator shall provide Sponsor with copies of all source documents.
    </div>
  </section>

  <!-- Publication Rights -->
  <section class="publication-section">
    <h2>&#128218; Publication Rights & Timing</h2>
    <p>Balancing academic freedom with patent protection and competitive interests.</p>

    <div class="publication-timeline">
      <div class="timeline-point">
        <div class="timeline-dot">1</div>
        <div class="timeline-label">Manuscript submitted for review</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">30d</div>
        <div class="timeline-label">Sponsor review period</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">60d</div>
        <div class="timeline-label">Patent filing delay (if needed)</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">90d</div>
        <div class="timeline-label">Maximum delay typical</div>
      </div>
    </div>

    <p style="font-size: 0.9rem; color: var(--gray-600); margin-bottom: 1rem;"><strong>Key negotiation points:</strong></p>
    <ul style="font-size: 0.9rem; color: var(--gray-600); margin-left: 1.5rem; margin-bottom: 1rem;">
      <li>Right to publish vs. discretionary approval</li>
      <li>Removal of confidential information only vs. substantive edits</li>
      <li>Patent filing delay rights and maximum duration</li>
      <li>Multi-site publication coordination (single vs. site-specific)</li>
      <li>Authorship and acknowledgment requirements</li>
    </ul>

    <div class="sample-clause">
      Investigator shall have the right to publish results of the Study, subject to the following: (a) Investigator shall submit proposed publications to Sponsor at least thirty (30) days before submission; (b) Sponsor may request deletion of Confidential Information and delay of publication up to sixty (60) additional days to file patent applications; (c) in no event shall total delay exceed ninety (90) days from manuscript submission; (d) for multi-center studies, Investigator agrees to participate in coordinated publication prior to individual site publications.
    </div>
  </section>

  <!-- IRB Alignment -->
  <section class="irb-section">
    <h2>&#128203; IRB Protocol Alignment</h2>
    <p>NDA confidentiality provisions must align with IRB-approved protocols and informed consent documents.</p>

    <div class="irb-grid">
      <div class="irb-item">
        <div class="irb-item-icon">&#128196;</div>
        <div>
          <h4>Consent Form Consistency</h4>
          <p>NDA data protections must not contradict promises made to research subjects.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128269;</div>
        <div>
          <h4>Protocol Scope</h4>
          <p>Confidential information use must align with IRB-approved research purposes.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128221;</div>
        <div>
          <h4>Amendment Coordination</h4>
          <p>Changes to data sharing may require IRB amendment approval.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128274;</div>
        <div>
          <h4>Retention Periods</h4>
          <p>Data retention must comply with both IRB and regulatory requirements.</p>
        </div>
      </div>
    </div>

    <div class="sample-clause">
      Investigator represents that the conduct of the Study and the handling of Confidential Information hereunder is consistent with the IRB-approved protocol and informed consent documents. Any modifications to data handling or confidentiality obligations that may affect research subjects shall be submitted for IRB review prior to implementation.
    </div>
  </section>

  <!-- Generator CTA -->
  <section class="generator-cta">
    <h2>Generate Your Clinical Trial NDA</h2>
    <p>Customize provisions for your specific trial collaboration, phase, and regulatory requirements.</p>
    <a href="/NDA/generator.html?scenario=clinical-trial" class="btn">Generate Clinical Trial NDA &#8594;</a>
  </section>

  <!-- Attorney Disclaimer -->
  <div class="attorney-disclaimer">
    <h4>&#9878;&#65039; Consult a Clinical Research Attorney</h4>
    <p>Clinical trial agreements involve complex FDA regulations, ICH-GCP requirements, and institutional policies. We strongly recommend having experienced clinical research counsel review any NDA involving human subjects research before execution. <a href="mailto:owner@terms.law">Request a consultation</a>.</p>
  </div>

</div>

<!-- Footer -->
<footer class="footer">
  <div class="footer-inner">
    <div>&copy; 2025 Terms.Law &mdash; Sergei Tokmakov, Esq. &bull; CA Bar #279869</div>
    <div class="footer-links">
      <a href="/NDA/">NDA Studio</a>
      <a href="./">Biotech Pack</a>
      <a href="mailto:owner@terms.law">Contact</a>
    </div>
  </div>
</footer>

<!-- Chat Widget -->
<script src="/chat-widget/chat-widget.js"></script>

</body>
</html>
